At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MRKR Marker Therapeutics, Inc.
Not Yet Opened 02-28 16:00:00 EST
1.53
+0.01
+0.33%
盘后1.53
+0.000.00%
18:58 EST
| High1.53 | Low1.45 | Vol25.67K |
| Open1.53 | D1 Closing1.53 | Amplitude5.25% |
| Mkt Cap16.38M | Tradable Cap9.98M | Total Shares10.71M |
| T/O38.22K | T/O Rate0.39% | Tradable Shares6.53M |
| P/B-- | ROE-- | EPS0.00 |
| 52wk High-- | 52wk Low-- | P/E-- |
| Dividend-- | Div.Yield-- | ROA-- |
data is loading...
Marker Therapeutics initiated with a Buy at Brookline
TIPRANKS · 02-10
BRIEF-Marker Therapeutics Inc Files For Resale Of Up To 10.1 Million Shares By The Selling Stockholders - SEC Filing
Reuters · 01-10
Marker Therapeutics Inc Files for Resale of up to 10.1 Mln Shares by the Selling Stockholders - SEC Filing
THOMSON REUTERS · 01-10
Marker Therapeutics to Raise $16.1 Million in Private Placement
MT Newswires Live · 2024-12-19
BRIEF-Marker Therapeutics Provides A Clinical Update On MT-601 In Patients With Lymphoma
Reuters · 2024-12-19
BUZZ-Marker Therapeutics slides after $16 mln private placement
Reuters · 2024-12-19
Marker Therapeutics sells 5.03M shares at $3.20 in private placement
TIPRANKS · 2024-12-19
Marker Therapeutics provides update on MT-601 patients
TIPRANKS · 2024-12-19
Marker Therapeutics Announces $16.1 Million Private Placement
THOMSON REUTERS · 2024-12-19
Marker Therapeutics Announces $16.1 Million Private Placement
GlobeNewswire · 2024-12-19
Marker Therapeutics Announces $16.1 Million Private Placement
Marker Therapeutics Provides a Clinical Update on Mt-601 in Patients With Lymphoma
THOMSON REUTERS · 2024-12-19
Marker Therapeutics Inc - Mt-601 Well Tolerated With No Icans Observed
THOMSON REUTERS · 2024-12-19
BRIEF-Marker Therapeutics Awarded $9.5 Mln Grant From The Cancer Prevention & Research Institute Of Texas (Cprit)
Reuters · 2024-12-17
Marker Therapeutics awarded $9.5M grant from CPRIT
TIPRANKS · 2024-12-17
Marker Therapeutics: Plans to Investigate Its Potential Application Beyond Lymphoma in Patients With Solid Tumors
THOMSON REUTERS · 2024-12-17
Marker Therapeutics Awarded $9.5 Million Grant From the Cancer Prevention & Research Institute of Texas (Cprit) to Support the Investigation of Mt-601 in Patients With Pancreatic Cancer
THOMSON REUTERS · 2024-12-17
Marker Therapeutics Inc: Anticipates Clinical Program Initiation in 2025
THOMSON REUTERS · 2024-12-17
Press Release: Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer
Dow Jones · 2024-12-17
Marker Therapeutics Leads 3 Noteworthy US Penny Stocks
Simply Wall St. · 2024-12-06
Marker Therapeutics Leads 3 Noteworthy US Penny Stocks
BRIEF-Marker Therapeutics Files For Mixed Shelf Of Up To $300 Million
Reuters · 2024-11-27
Introduction
Company Name.
Marker Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
Issue price:
--
Invest in Global Markets with Tiger Brokers!Open App